DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Diabetic Macular Edema - Pipeline Review, H2 2016" drug pipelines to their offering.
This report provides comprehensive information on the therapeutic development for Diabetic Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Diabetic Macular Edema Overview
- Therapeutics Development
- Pipeline Products for Diabetic Macular Edema - Overview
- Pipeline Products for Diabetic Macular Edema - Comparative Analysis
- Diabetic Macular Edema - Therapeutics under Development by Companies
- Diabetic Macular Edema - Therapeutics under Investigation by Universities/Institutes
- Diabetic Macular Edema Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Diabetic Macular Edema - Products under Development by Companies
- Diabetic Macular Edema - Products under Investigation by Universities/Institutes
- Diabetic Macular Edema - Companies Involved in Therapeutics Development (Partial List)
- Aciont Inc.
- ActiveSite Pharmaceuticals, Inc.
- Adverum Biotechnologies, Inc.
- Aerpio Therapeutics, Inc.
- Allergan Plc
- Ampio Pharmaceuticals, Inc.
- Araim Pharmaceuticals, Inc.
- Astellas Pharma Inc.
- Boehringer Ingelheim GmbH
- Chengdu Kanghong Pharmaceuticals
For more information about this drug pipelines visit http://www.researchandmarkets.com/research/b7vp8q/diabetic_macular